The interplay between hypertension and COVID-19 could lead to a synergistically increased risk for adverse outcomes due to a decrease in levels of expression of ACE2, due to the use of its of inhibitors that facilitate further entry of SARS-CoV-2 [170]. This evidence concerns the gene ACE2 and COVID-19.